1. Home
  2. OSRH vs HCWB Comparison

OSRH vs HCWB Comparison

Compare OSRH & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OSR Holdings Inc.

OSRH

OSR Holdings Inc.

HOLD

Current Price

$0.36

Market Cap

17.9M

Sector

N/A

ML Signal

HOLD

HCWB

HCW Biologics Inc.

HOLD

Current Price

$4.52

Market Cap

14.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OSRH
HCWB
Founded
N/A
2018
Country
United States
United States
Employees
22
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.9M
14.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
OSRH
HCWB
Price
$0.36
$4.52
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$35.00
AVG Volume (30 Days)
549.9K
473.9K
Earning Date
05-19-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.37
Revenue
N/A
$4,099,750.00
Revenue This Year
$9.30
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$12.05
Revenue Growth
N/A
N/A
52 Week Low
$0.30
$0.25
52 Week High
$1.24
$7.35

Technical Indicators

Market Signals
Indicator
OSRH
HCWB
Relative Strength Index (RSI) 48.26 70.51
Support Level $0.30 $0.59
Resistance Level $0.45 $4.88
Average True Range (ATR) 0.03 0.34
MACD 0.01 0.16
Stochastic Oscillator 76.69 77.05

Price Performance

Historical Comparison
OSRH
HCWB

About OSRH OSR Holdings Inc.

OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea. The company's pipeline products include: Vaximm, Darnatein, Woori IO, and RMC.

About HCWB HCW Biologics Inc.

HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.

Share on Social Networks: